<sub id="h9hdp"></sub>
      <span id="h9hdp"></span>
        <sub id="h9hdp"></sub>
        <sub id="h9hdp"></sub>

        <address id="h9hdp"></address>

          <thead id="h9hdp"></thead>

            Assessment of TLR immunomodulators in oncology and HIV

            Project Challenge: 
            Learn More

            Deal benchmarks & term sheet appraisal for an early-stage license deal

            Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...
            Learn More

            Investor due diligence of a development-stage microbiome company

            Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
            Learn More

            Investor Due Diligence: Pharma Business Development Case Studies

            Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
            Learn More

            Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

            An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
            Learn More

            Pharmaceutical Licensing: Negotiation Support

            Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
            Learn More

            Due diligence: biologic technologies & phase III probability of success of CNS asset

            Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
            Learn More

            Due diligence: plasma protein manufacturer; Phase III gene therapy asset

            Case Study 1, Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in...
            Learn More

            Developing an independent market report for a cannabinoid company seeking a dual-listing

            Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
            Learn More

            Roadmap for commercial data infrastructure build to support rare disease drug launch

            Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...
            Learn More

            University life sciences IP and project portfolio review

            Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...
            Learn More

            Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

            Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita was...
            Learn More
            中文无码人妻影音先锋